Category: Latest News
-
Dollar Falters as Euro Advances; Market Awaits U.S. Inflation Data
The U.S. dollar made a slight move upward in early Friday trading but stayed pinned near its lowest levels in over two years, weighed down by fading geopolitical tensions and improving global trade sentiment. In contrast, the euro continued to strengthen, supported by upbeat inflation figures from key eurozone economies. Dollar Faces Headwinds from Easing…
-
Nasdaq, S&P 500 Close Just Shy Of Record Highs
After ending the previous session little changed, stocks showed a strong move to the upside over the course of the trading day on Thursday. With the upward move, the Nasdaq and the S&P 500 ended the day just shy of their record closing highs. The major averages all posted strong gains on the day. The…
-
Julong Holding Shares Surge 55% in Debut on Nasdaq
Julong Holding Limited (NASDAQ:JLHL) made a strong market entry Thursday, with its stock climbing 55% above its IPO price to close at $6.21 per share. The company initially priced its offering at $4.00 per share. The firm, known for delivering smart integrated solutions, sold 1.25 million Class A ordinary shares during its public offering, raising…
-
Aldeyra Shares Climb on FDA Backing for PVRL Drug Trial Design
Aldeyra Therapeutics Inc. (NASDAQ:ALDX) saw its stock rise by 8% after announcing a key agreement with the U.S. Food and Drug Administration (FDA) concerning its planned clinical trial for ADX-2191, a treatment candidate for primary vitreoretinal lymphoma (PVRL), a rare and aggressive eye cancer. The company received a Special Protocol Assessment (SPA) Agreement Letter from…
-
Goldman Sachs Stock Reaches Record High on Buybacks and Market Momentum
Goldman Sachs Group Inc. (NYSE:GS) has reached a new all-time high, with shares climbing to $672.46. This milestone reflects a strong 50.42% gain over the past year, underscoring growing investor confidence in the global financial powerhouse. The firm’s surge has been fueled by a mix of strategic initiatives, including aggressive stock buybacks and a favorable…
-
Disney Shares Climb to 52-Week High, Fueled by Strategic Deals and Analyst Optimism
The Walt Disney Company (NYSE:DIS) stock surged to a new 52-week peak of $120.67, bringing its market capitalization to $216 billion. The milestone reflects a strong year of gains, with shares rising 18.4% over the past 12 months, underpinned by a 5.4% revenue growth and a price-to-earnings ratio of 24.3. Disney’s solid performance is being…
-
Ascent Solar Shares Skyrocket on NASA Partnership for Beamed Power Innovation
Ascent Solar Technologies Inc. (NASDAQ:ASTI) saw its stock soar 160% after revealing a new collaboration with NASA aimed at advancing space-based beamed power technology using the company’s cutting-edge CIGS thin-film solar modules. Under a newly signed 12-month Collaborative Agreement Notice (CAN), Ascent will partner with NASA’s Marshall Space Flight Center and Glenn Research Center to…
-
Serve Robotics Shares Climb on Atlanta Launch, Expanding Autonomous Delivery Footprint
Shares of Serve Robotics Inc. (NASDAQ:SERV) rose 4.8% after the company announced its expansion into the Atlanta metropolitan area, marking a significant step in its nationwide growth strategy for autonomous sidewalk delivery. The move brings Serve’s delivery robots to neighborhoods such as Midtown, Old Fourth Ward, and Downtown Atlanta, offering service to more than 50,000…
-
Edgewise Therapeutics Shares Drop After FDA Withholds Accelerated Approval for Muscle Disorder Drug
Edgewise Therapeutics Inc. (NASDAQ:EWTX) saw its shares slide by 7.2% after the U.S. Food and Drug Administration (FDA) concluded that current data from the company’s CANYON trial does not meet the threshold for accelerated approval of sevasemten, its experimental treatment for Becker muscular dystrophy. Despite encouraging signs from the MESA open-label extension trial, which showed…
-
Vor Biopharma Shares Skyrocket on Global Licensing Deal for Autoimmune Therapy
Vor Biopharma Inc. (NASDAQ:VOR) saw its stock surge by 85% after unveiling a major licensing agreement with RemeGen Co., Ltd., a biotech firm based in China. The partnership grants Vor exclusive global rights—excluding China, Hong Kong, Macau, and Taiwan—to develop and commercialize telitacicept, an innovative fusion protein targeting autoimmune disorders. As part of the deal,…